← Patent-cliff monitor Loss of exclusivity December 2043 latest FDA-listed patent expiry
Company Biofrontera → See this company's full patent-cliff portfolio Drug detail Brand name AMELUZ Active ingredient AMINOLEVULINIC ACID HYDROCHLORIDE Strength 10% Dosage form GEL Route TOPICAL Modality Small molecule FDA approval May 2016 Marketing status RX
Listed patents Patent Expires Type 12280146 December 2043 product 11235169 October 2040 use U-3303 11540981 February 2028 product
Regulatory exclusivity Code Expires D-194 October 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.